Lineage Cell Therapeutics (LCTX) Debt Ratio (2014 - 2021)

Lineage Cell Therapeutics (LCTX) posted quarterly Debt Ratio of 0.0 for Q1 2021, down 15.62% quarter-over-quarter from 0.0 in Q4 2020.

Lineage Cell Therapeutics (LCTX) Debt Ratio (2014 - 2021) Analysis & Trends

Lineage Cell Therapeutics' Debt Ratio history runs 6 years deep, the most recent figure standing at 0.0 for Q1 2021.

In Q1 2021, Debt Ratio changed N/A year-over-year to 0.0; the TTM figure through Mar 2021 stood at 0.0 (changed N/A YoY), while the FY2020 annual figure was 0.0, changed N/A from the prior year.
Debt Ratio for Q1 2021 stood at 0.0, down from 0.0 in the prior quarter.
The five-year high for Debt Ratio was 0.01 in Q3 2020, with the low at 0.0 in Q4 2017.
The 3-year median for Debt Ratio is 0.0 (2021), against an average of 0.0.
Peak annual rise in Debt Ratio reached 70.37% in 2017, while the deepest fall reached 87.66% in 2017.
Lineage Cell Therapeutics' Debt Ratio stood at 0.0 in 2017, then soared by 4562.96% to 0.0 in 2020, then decreased by 15.62% to 0.0 in 2021.
Business Quant data shows LCTX's Debt Ratio at 0.0 in Q1 2021, 0.0 in Q4 2020, and 0.01 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Lineage Cell Therapeutics	270.61 Mn	212.77 Mn	1.07 Mn	-

Download Data